Ishizawa Y, Totsuka E, Umehara M, Nishimura A, Ono H, Sasaki M
Second Department of Surgery, Hirosaki University School of Medicine, Hirosaki, Japan.
Transplant Proc. 2004 Oct;36(8):2344-8. doi: 10.1016/j.transproceed.2004.06.038.
The use of bioartificial liver devices requires. A sufficient liver cell mass to provide adequate metabolic support, reduction of xenogeneic immune reactions, and avoidance of viral transmission. We have developed a plasmapheresis system using a semipermeable membrane combined with canine whole liver perfusion (PMCWLP). In this study, we investigated the efficacy of our system in a porcine fulminant hepatic failure (FHF) model.
The porcine FHF model was established by intraportal administration of alpha-amanitin (0.1 mg/kg) and lipopolysaccharide (1 microg/kg). Nine hours after drug injection, xenogenic perfusion treatment was performed twice within 6 hours (n = 5). As the plasmapheresis device, we used a hollow-fiber module with cellulose diacetate porous fibers (pore size, 0.05 microm, surface area, 2 m2). The canine whole liver was perfused with modified Krebs solution, which is commonly used in many laboratories, containing albumin (2 g/dL) and glucose (300 mg/dL). Control pigs (n = 10), had the circuit not connected to the whole canine liver.
The survival of FHF pigs was significantly increased by the treatment (58.9 +/- 21.8 hour) compared with the controls (22.3 +/- 8.1 hour). Mean blood ammonia levels and intracranial pressure during treatment were significantly lower compared with control groups.
Treatment of FHF pigs with the system significantly increased survival time, suggesting that this method may have applications as a clinical liver assist device.
生物人工肝装置的使用需要足够的肝细胞量,以提供充分的代谢支持,减少异种免疫反应,并避免病毒传播。我们开发了一种使用半透膜结合犬全肝灌注的血浆置换系统(PMCWLP)。在本研究中,我们在猪暴发性肝衰竭(FHF)模型中研究了该系统的疗效。
通过门静脉注射α-鹅膏蕈碱(0.1mg/kg)和脂多糖(1μg/kg)建立猪FHF模型。药物注射9小时后,在6小时内进行两次异种灌注治疗(n = 5)。作为血浆置换装置,我们使用了具有二醋酸纤维素多孔纤维(孔径0.05μm,表面积2m²)的中空纤维模块。犬全肝用改良的Krebs溶液灌注,该溶液在许多实验室中常用,含有白蛋白(2g/dL)和葡萄糖(300mg/dL)。对照猪(n = 10),其回路未连接到犬全肝。
与对照组(22.3±8.1小时)相比,治疗组FHF猪的存活时间显著延长(58.9±21.8小时)。治疗期间的平均血氨水平和颅内压与对照组相比显著降低。
用该系统治疗FHF猪显著延长了存活时间,表明该方法可能作为一种临床肝脏辅助装置具有应用价值。